Vidofludimus calcium is under clinical development by Immunic and currently in Phase II for Primary Progressive Multiple Sclerosis (PPMS). According to GlobalData, Phase II drugs for Primary Progressive Multiple Sclerosis (PPMS) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vidofludimus calcium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vidofludimus calcium overview
Vidofludimus calcium (IMU-838) is under development for the treatment of relapsing-remitting multiple sclerosis, progressive multiple sclerosis and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primary progressive multiple sclerosis (ppms) and secondary progressive multiple sclerosis (spms). The drug candidate is administered by oral route. It is a calcium salt of vidofludimus. It targets dihydroorotate dehydrogenase (DHODH) andNurr1 (Nuclear receptor related 1). It was under development for the treatment of ulcerative colitis, primary sclerosing cholangitis and crohn's disease.
Immunic overview
Immunic (Immunic Therapeutics) is a biopharmaceutical company that discover, develops and commercializes oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company’s pipeline products include IMU-838, a selective immune modulator for the treatment of relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), other chronic inflammatory and autoimmune diseases; IMU-856, an orally small molecule modulator to treat intestinal barrier function; and IMU-935, an immunology therapy targeting ROR?t and Th17. It also evaluating therapies targeting primary sclerosing cholangitis (PSC) and guillain-barre syndrome (GBS).The company has operations in Germany, Australia and the US. Immunic Therapeutics is headquartered in New York City, New York, the US.
For a complete picture of Vidofludimus calcium’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
